Montana State University Billings

Announces Appointments of Kevin Freeman as Chief Growth Officer, Tarah Neujahr Bryan as Chief Marketing Officer, and Dave Ross as Chief Technology Officer SALT LAKE CITY, Sept. 7, 2022 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced three new leadership assignments in support of its strategic focus areas moving forward. These strategic focus areas center around strengthening and deepening existing client relationships to enable greater success in realizing massive, measurable, data-informed improvement while continuing to add new client relationships. This strategic focus includes the appointment of the company's current Chief Revenue Officer, Kevin Freeman, as Chief Growth Officer, and current Chief Brand and Communications Officer, Tarah Neujahr Bryan, as Chief Marketing Officer, effective September 7, 2022. In these roles, Kevin and Tarah will be responsible for the strategic growth functions at Health Catalyst, with a primary focus on expanding existing client relationships, and Kevin and Tarah will each report directly to Chief Executive Officer Dan Burton. Kevin Freeman came to Health Catalyst in 2020 as part of the Vitalware acquisition, bringing 20+ years of healthcare IT growth leadership experience including publicly traded, private equity, and venture-capital-backed companies. He has a successful track record of building results-driven teams, strengthening client partnerships, and driving business development growth. Kevin has a Bachelor of Arts in Sociology from the University of Texas at Arlington. Tarah Neujahr Bryan joined Health Catalyst in 2013 and has served as Editorial Director, Senior Vice President of Marketing, and Chief Brand and Communications Officer. She brings a breadth of marketing and communications experience to her current role. Prior to joining Health Catalyst, Tarah served as the Marketing Communications Director and the Foundation Executive Director at a community hospital, managed at an advertising agency, was the Editor and Operations Manager at an archaeology firm, and provided triage assistance and patient admissions at a Level-II Trauma Center. She has a Master of Arts in Journalism and Mass Communications from the University of Nebraska and a Bachelor of Arts from Montana State University-Billings. Health Catalyst has also named Dave Ross, current Associate Chief Technology Officer, as Chief Technology Officer, also effective September 7, 2022. He will play a critical technology leadership role in building and enabling a world-class data and analytics infrastructure to support clients' efforts towards massive improvement in critical use-case areas such as tech-enabled outsourcing, financial empowerment, population health, and clinical improvement. Dave Ross joined Health Catalyst in 2021 as part of the Twistle acquisition, and was previously the Chief Technology Officer and Co-Founder of Twistle, leading all product development and engineering activities for over ten years prior to Twistle being acquired by Health Catalyst. Before starting Twistle, Dave was the Director of Information Systems at Albany Medical Center in New York. He has built and led software development initiatives across healthcare and educational technology sectors and is passionate about finding the perfect intersection between engineering excellence and delivering business value. Dave holds a Bachelor of Science in Information Systems from SUNY Empire State College. "This is a pivotal time for Health Catalyst as we work toward enabling the positive transformation of care for every patient served by our healthcare clients," said Chief Executive Officer Dan Burton. "I am grateful for each of these three world-class leaders moving into key positions, providing them with an increased opportunity to deliver on our long-term growth and vision to sustain our critical mission of being a catalyst, in deep partnership with our clients, to enable massive, measurable, data-informed healthcare improvement." Related to the new growth leadership assignments, effective September 30, 2022, Patrick Nelli will transition from his role as President to that of Senior Advisor, where he will primarily focus on enabling a smooth transition of his prior responsibilities as President to Kevin Freeman, Chief Growth Officer, and to Dan Burton, Chief Executive Officer. Patrick joined Health Catalyst in 2013 and has played various roles contributing to the company's success, including as Chief Financial Officer from 2017 to January 2021, and as President from January 2021 to the present. Also, effective September 30, 2022, Bryan Hinton will complete his tenure at Health Catalyst. Bryan has contributed to Health Catalyst's growth and success in a number of roles since he joined the company in 2012, including most recently in the role of Chief Technology Officer. Dan Burton shared, "I want to extend my heartfelt gratitude to Patrick and to Bryan for their many years of service and dedication to our mission, and for their incredible expertise and leadership in various roles over the years. They have deeply contributed to our company's mission, growth, and success. We are truly grateful to these outstanding colleagues, and we wish them continued success in their future endeavors." About Health Catalyst Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed. Media Contact: Tarah Neujahr Bryan, Chief Marketing Officer [email protected] SOURCE Health Catalyst

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company's Board of Directors, effective immediately. "We are excited to welcome Dr. Martell and Dr. Jacobs to the board", commented Rick Stewart, Achieve's Executive Chairman of the Board of Directors. "Dr. Martell's clinical development experience compliments that of Dr. Jacobs, providing the company with depth of knowledge, particularly in the field of addiction, which is critically important for our continued success." Dr. Martell brings an impressive and diverse background of scientific, clinical, and leadership experience to the team. She is board certified in both Internal and Addiction Medicine, served over 20 years as a practicing physician at Yale, and remains active there as an Entrepreneur in Residence at the Office of Cooperative Research. She has been a pivotal leader in the development and success of numerous marketed products across multiple therapeutic categories and has held leadership and executive roles at Pfizer, Kura Oncology, and Juniper Pharmaceuticals. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. Dr. Jacobs currently serves as Achieve's President and Chief Medical Officer. In addition to her board appointment, she will continue in this role leading the regulatory and clinical development efforts for cytisinicline. Dr. Jacobs brings over 30 years of experience in the industry, leading multiple development programs and product regulatory approvals. She has previously held leadership and executive roles at OncoGenex, Corixa, and Immunex. Dr. Jacobs received her Bachelor's in Microbiology from Montana State University, her Master's and Ph.D. in Veterinary Pathology/Microbiology from Washington State University, and an M.D. from the University of Washington Medical School. About Achieve and Cytisinicline Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2 Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking. Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S. Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development activities, the potential market size and market acceptance for cytisinicline, the potential benefits of cytisinicline and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. Media Contact Glenn Silver Glenn.Silver@Finnpartners.com (646) 871-8485 Investor Relations Contact Jason Wong jwong@bplifescience.com (415) 375-3340 ext. 4 SOURCE: Achieve Life Sciences, Inc. View source version on accesswire.com: